Mariner
MDGL icon

Mariner’s Madrigal Pharmaceuticals MDGL Stock Holding History

Mariner’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-567
Closed -$296K – 3769
2026
Q1 		$296K Sell
567
-1,859
-77% -$888K ﹤0.01% 2886
2025
Q4 		$1.41M Buy
2,426
+605
+33% +$309K ﹤0.01% 1706
2025
Q3 		$835K Buy
1,821
+271
+17% +$101K ﹤0.01% 2045
2025
Q2 		$469K Sell
1,550
-334
-18% -$99.5K ﹤0.01% 2384
2025
Q1 		$624K Buy
1,884
+138
+8% +$45.3K ﹤0.01% 2022
2024
Q4 		$539K Sell
1,746
-1,252
-42% -$352K ﹤0.01% 2138
2024
Q3 		$636K Buy
2,998
+110
+4% +$28.1K ﹤0.01% 1942
2024
Q2 		$809K Buy
2,888
+255
+10% +$60.7K ﹤0.01% 1660
2024
Q1 		$703K Buy
2,633
+1,371
+109% +$323K ﹤0.01% 1770
2023
Q4 		$292K Buy
+1,262
New +$221K ﹤0.01% 2377
2023
Q1 		– Sell
-730
Closed -$212K – 2840
2022
Q4 		$212K Buy
+730
New +$71.4K ﹤0.01% 2310

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mariner's MDGL Position: Q2 2026 in Review

Mariner sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 567 shares — an estimated $296K sold.

Mariner first reported a position in MDGL in Q4 2022 and held it in 11 quarters. The position peaked at $1.41M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Mariner reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Mariner sold 567 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $296K.
  • Mariner first reported a position in Madrigal Pharmaceuticals in Q4 2022 and held it in 11 quarters.
  • Mariner's Madrigal Pharmaceuticals position peaked at $1.41M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.